---
title: CDMO Daily News — September 15, 2026
slug: daily-news-2026-09-15-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 15 CDMO daily: Astellas Doubles Tralee Aseptic Capacity With Second Filling Line by 2029; Interlabor's Dual-Path Troubleshooting Framework Cuts…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-15-cdmo
published_at: 2026-09-15T00:00:46.593Z
last_updated: 2026-09-15T00:02:39.377Z
---

### Astellas Doubles Tralee Aseptic Capacity With Second Filling Line by 2029
- Astellas Ireland is installing a second aseptic filling line at its Kerry Technology Park facility in Tralee, doubling drug-product manufacturing capacity.
- The expansion, supported by IDA Ireland, will create skilled roles across engineering, production, quality, and logistics, with completion targeted for 2029.
- The project follows Astellas' €330 million investment in a new Kerry facility opening in early 2027, extending the company's global manufacturing footprint.

**Operational Impact**

Astellas' Tralee facility expansion adds EMEA aseptic fill-finish capacity and signals sustained investment in Ireland-based commercial manufacturing, relevant to CDMO directors evaluating regional supply-chain resilience and capacity availability for biologics nearing launch.

*Source: [PharmaSource RSS](https://pharmasource.global/content/manufacturing/manufacturing-news/astellas-expands-ireland-facility-with-second-aseptic-filling-line)*

---

These back-to-back developments pull in opposite directions on capacity and risk—outsourcing leaders should reconcile both signals against each active program rather than treating either headline as sector-wide consensus.

### Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days
- [Interlabor Belp AG](/companies/interlabor-belp-ag) demonstrated a structured five-step troubleshooting workflow that runs parallel hypotheses simultaneously, reducing investigation timelines without sacrificing scientific rigor.
- Two case studies—benzene contamination in finished product and unknown residue in production pipe—showed how dedicated instruments, on-site sampling, and adaptive method selection resolved root causes in days rather than weeks.

**Operational Impact**

CDMO directors evaluating analytical troubleshooting partners should note Interlabor's dedicated instrument fleet and on-site sampling capability as a differentiator for accelerating contamination and process-deviation investigations that would otherwise delay commercial manufacturing.

*Source: [PharmaSource RSS](https://pharmasource.global/content/podcast/how-to-identify-a-root-cause-without-delay-interlabors-troubleshooting-framework)*

## References

1. [PharmaSource RSS — Astellas Doubles Tralee Aseptic Capacity With Second Filling Line by 2029](https://pharmasource.global/content/manufacturing/manufacturing-news/astellas-expands-ireland-facility-with-second-aseptic-filling-line)
2. [PharmaSource RSS — Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days](https://pharmasource.global/content/podcast/how-to-identify-a-root-cause-without-delay-interlabors-troubleshooting-framework)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-15-cdmo